Saturday 17 October 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6% and free cash flow fell 43.0%, each against the same quarter a year earlier.
71.93
1.94
−2.63%
Follow ORKA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
22.37 | 28.89 | 59.01 | 37.72 | 15.56 | 14.28 | 9.16 | 8.55 | 5.94 | 8.95 |
Net Debt/EBITDA |
2.65 | 4.16 | 5.21 | 4.05 | 2.77 | 5.07 | 1.46 | 0.82 | 0.64 | 1.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.84 | 0.69 | 0.94 | 1.10 | 0.97 | 0.79 | 0.88 | 1.04 | 0.94 | 0.91 |
Capex/Depreciation |
0.04 | 0.09 | 0.00 | (0.02) | (0.47) | (0.20) | (0.04) | (0.17) | (0.01) | (0.02) |
Interest Coverage |
— | (60.03) | — | (15.70) | — | (1,085.11) | (830.57) | (1,014.75) | (3,118.67) | (98.30) |
| (24.86%) | (40.22%) | (13.57%) | (21.41%) | (39.61%) | (35.98%) | (80.37%) | (97.30%) | (113.89%) | (54.57%) | |
| (23.84%) | (38.59%) | (13.19%) | (20.26%) | (36.68%) | (33.03%) | (71.38%) | (82.68%) | (99.96%) | (51.23%) | |
ROIC |
(56.55%) | (837.93%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,007.09%) |
Return on Tangible Assets |
(32.07%) | (23.00%) | (14.44%) | (23.87%) | (37.91%) | (20.95%) | (72.47%) | (132.04%) | (180.02%) | (86.03%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.94) | (3.46) | (4.18) | (9.09) | (16.24) | (19.74) | (43.68) | (128.67) | (361.80) | (357.12) |
Cash per Share |
7.39 | 22.37 | 31.17 | 35.36 | 46.07 | 125.09 | 76.03 | 103.09 | 243.31 | 503.88 |
Shareholders Equity per Share |
10.35 | 22.77 | 30.83 | 34.72 | 44.07 | 118.59 | 69.18 | 94.10 | 212.73 | 528.43 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.35 | 22.77 | 30.83 | 34.72 | 44.07 | 118.59 | 69.18 | 94.10 | 212.73 | 528.43 |
Free Cash Flow |
(88.42) | (58.03) | (5.01) | (10.91) | (18.80) | (7.74) | (4.80) | (8.25) | (17.47) | (15.00) |
Working Capital |
328.48 | 363.83 | 36.96 | 41.57 | 50.92 | 46.47 | 7.55 | 5.98 | 10.23 | 19.05 |
Capital Expenditures |
(0.21) | (0.19) | — | 0.00 | (0.04) | (0.02) | 0.00 | 0.00 | 0.00 | (0.01) |
Net Current Asset Value |
327.17 | 363.07 | 36.75 | 41.29 | 50.54 | 46.06 | 7.55 | 5.98 | 10.21 | 19.01 |
| Other line items | ||||||||||
Quick Ratio |
21.92 | 28.80 | 58.76 | 37.50 | 15.25 | 14.02 | 9.03 | 8.33 | 5.68 | 8.83 |
Depreciation/Fixed assets |
(17.08) | (13.69) | 11.10 | 4.56 | 1.90 | 4.43 | 8.90 | 1.00 | 11.31 | 7.29 |
Cash ROIC |
(10.93%) | (7.66%) | (6.73%) | (12.97%) | (18.01%) | (8.10%) | (30.08%) | (65.25%) | (79.33%) | (34.59%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.93) | (3.44) | (4.18) | (9.09) | (16.20) | (19.69) | (43.65) | (128.61) | (361.74) | (356.83) |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | (0.04) | (0.05) | (0.04) | (0.06) | (0.06) | (0.29) |
Average Payables |
6.82 | 4.92 | 0.35 | 0.73 | 1.45 | 1.10 | 0.32 | 0.43 | 0.91 | 0.78 |
Average Assets |
442.32 | 216.94 | 40.47 | 49.00 | 52.68 | 29.48 | 7.68 | 9.60 | 18.50 | 32.10 |
Average Common Equity |
424.14 | 208.16 | 39.35 | 46.36 | 48.78 | 27.07 | 6.82 | 8.15 | 16.23 | 30.13 |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates